Advanced RET-rearranged NSCLC

Bookmark and Share
Published: 6 Jun 2016
Views: 2070
Dr Takashi Seto and Dr Kiyotaka Yoh

Dr Seto (National Kyushu Cancer Center, Kyushu, Japan) and Dr Yoh (National Cancer Center Hospital East, Kashiwa, Japan) talk to ecancertv at ASCO 2016 about RET fusions, known oncogenes from a small subset of non-small cell lung cancer  (NSCLC).

Out of 196 institutions in Japan (LC-SCRUM-Japan), 17 RET-rearranged patients who had previously failed to respond to chemotherapy were given vandetanib, a TKI with RET kinase activity.

Dr Seto and Dr Yoh report that vandetanib increased anti-tumour activity, progression free survival and and partial response rates, especially among those from the CCDC6-RET subtype.

ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.